Multivalent heteromultimer scaffold design and constructs

Patent metadata

Field	Value
Publication number	US-10155803-B2
Application number	US-201615355007-A
Country	US
Kind code	B2
Filing date	Nov 17, 2016
Priority date	Mar 3, 2011
Publication date	Dec 18, 2018
Grant date	Dec 18, 2018

Abstract

Provided herein are multifunctional heteromer proteins. In specific embodiments is a heteromultimer that comprises: at least two monomeric proteins, wherein each monomeric protein comprises at least one cargo polypeptide, attached to a transporter polypeptide, such that said monomeric proteins associate to form the heteromultimer. These therapeutically novel molecules comprise monomers that function as scaffolds for the conjugation or fusion of therapeutic molecular entities resulting in the creation of bispecific or multivalent molecular species.

First claim

What is claimed:

1. One or a combination of two or more nucleic acid molecules encoding a heteromultimer, the heteromultimer comprising:
a first protein that comprises (i) a first transporter polypeptide comprising a first segment of albumin; and (ii) at least one cargo polypeptide and
a second protein that comprises (iii) a second transporter polypeptide comprising a second segment of albumin; and (iv) at least one cargo polypeptide,
wherein said first segment of albumin and said second segment of albumin are derived from an albumin by segmentation of the albumin, said first transporter polypeptide is different from said second transporter polypeptide, and said transporter polypeptides self-assemble to form a quasi-native albumin structure.

2. The nucleic acid molecules according to claim 1 , wherein said heteromultimer is a heterodimer.

3. The nucleic acid molecules according to claim 2 , wherein the first segment of albumin and the second segment of albumin form a complementary pair of transporter polypeptides.

4. The nucleic acid molecules according to claim 1 , wherein the first segment of albumin and said second segment of albumin are derived from an albumin by segmentation of the albumin to remove a loop.

5. The nucleic acid molecules according to claim 1 , wherein said first transporter polypeptide and said second transporter polypeptide are derived from a mammalian albumin.

6. The nucleic acid molecules according to claim 5 , wherein the first transporter polypeptide and the second transporter polypeptide are derived from the same type of albumin.

7. The one nucleic acid molecules according to claim 6 , wherein said first transporter polypeptide and said second transporter polypeptide are derived from the same alloalbumin.

8. The nucleic acid molecules according to claim 5 , wherein the transporter polypeptides are derived from different albumins.

9. The nucleic acid molecules according to claim 8 , wherein:
a. at least one transporter polypeptide is derived from an alloalbumin;
b. at least one transporter polypeptide is derived from human serum albumin;
c. one of said first transporter polypeptide and said second transporter polypeptide is derived from an alloalbumin and the other is derived from a different alloalbumin, or
d. one of said first transporter polypeptide and said second transporter polypeptide is derived from human serum albumin and the other is derived from an alloalbumin.

10. The nucleic acid molecules according to claim 5 , wherein the mammalian albumin is human serum albumin.

11. The nucleic acid molecules according to claim 5 , wherein said first transporter polypeptide has an amino acid sequence comprising SEQ ID NO:2 or an analog or variant thereof, and wherein said second transporter polypeptide has an amino acid sequence comprising SEQ ID NO:3 or an analog or variant thereof.

12. The nucleic acid molecules according to claim 11 , wherein one nucleic acid has a nucleotide sequence comprising SEQ ID NO:6 or an analog or variant thereof, and another nucleic acid has a nucleotide sequence comprising SEQ ID NO:7 or an analog or variant thereof.

13. The nucleic acid molecules according to claim 5 , wherein said first transporter polypeptide has an amino acid sequence comprising SEQ ID NO:8 or an analog or variant thereof, and wherein said second transporter polypeptide has an amino acid sequence comprising SEQ ID NO:10 or an analog or variant thereof.

14. The nucleic acid molecules according to claim 13 , wherein one nucleic acid has a nucleotide sequence comprising SEQ ID NO:9 or an analog or variant thereof, and another nucleic acid has a nucleotide sequence comprising SEQ ID NO:11 or an analog or variant thereof.

15. The nucleic acid molecules according to claim 1 , wherein said first transporter polypeptide and said second transporter polypeptide are derived from a non-mammalian albumin.

16. The nucleic acid molecules according to claim 1 , wherein at least one cargo polypeptide is an antibody, or a fragment or variant thereof.

17. The one nucleic acid molecules according to claim 1 , wherein the at least one cargo polypeptide of said first protein binds a target antigen, and the at least one cargo polypeptide of said second protein comprises a toxin moiety.

18. The nucleic acid molecules according to claim 1 , wherein said at least one cargo polypeptide binds a target antigen, wherein said target antigen is at least one of alpha-chain (CD25) of IL-2R, Amyloid beta, anti-EpCAM, anti-CD3, CD16, CD20, CD22, CD23, CD3, CD4, CD52, CD80, CTLA-4, EGFR, EpCAM, F protein of RSV, G250, glycoprotein IIB/IIIa R, HER2, HSP90, IgE antibody, IL-12, IL-23, IL-1beta, IL-5, IL-6, RANKL, TNF alpha, TNFR, VEGF-A, glucagon receptor, GLP receptor, and LDL receptor.

19. The nucleic acid molecules according to claim 1 wherein at least one cargo polypeptide is an enzyme, hormone, therapeutic polypeptide, antigen, chemotoxin, cytokine or a variant or fragment thereof.

20. The nucleic acid molecules according to claim 1 , wherein said first protein and said second protein comprise the same cargo polypeptide.

21. The nucleic acid molecules according to claim 1 , wherein the cargo polypeptide is attached to the transporter polypeptide by direct fusion or fusion via a linker.

22. The nucleic acid molecules according to claim 21 , wherein the linker is a GGSG linker or a (GGSG)4GG linker.

23. The nucleic acid molecules according to claim 1 , wherein the heteromultimer binds to FcRn.

24. The nucleic acid molecules according to claim 1 , wherein the first protein and the second protein comprise different cargo polypeptides.

25. The nucleic acid molecules according to claim 1 , wherein the first protein comprises at least two different cargo polypeptides, or the second protein comprises at least two different cargo polypeptides.

26. One or more vectors comprising the nucleic acid molecules according to claim 1 .

27. A method of expressing a heteromultimer in mammalian or yeast cells, the method comprising:
a) transfecting at least one mammalian or yeast cell with the nucleic acid molecules according to claim 1 , to produce at least one transfected mammalian or yeast cell; and
b) culturing said at least one transfected mammalian or yeast cell under conditions suitable for expressing the heteromultimer.

Assignees

• Zymeworks Inc

Inventors

• Dixit Surjit Bhimarao
• D'Angelo Igor Edmondo Paolo
• Poon David Kai Yuen

Classifications

• C12Y304/21061

  Kexin (3.4.21.61), i.e. proprotein convertase subtilisin/kexin type 9 · CPC title

• A61P31/00

  Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title

• C07K14/47

  from mammals · CPC title

• C07K14/79

  Transferrins, e.g. lactoferrins, ovotransferrins · CPC title

• C07K14/485

  Epidermal growth factor [EGF], i.e. urogastrone · CPC title